Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb:63:1-9.
doi: 10.1016/j.cytogfr.2022.02.002. Epub 2022 Feb 12.

The Coronavirus pandemic - 2022: Viruses, variants & vaccines

Magdalini Alexandridi  1 , Julija Mazej  1 , Enrico Palermo  1 , John Hiscott  2
Affiliations

The Coronavirus pandemic - 2022: Viruses, variants & vaccines

Magdalini Alexandridi et al. Cytokine Growth Factor Rev. 2022 Feb.

Abstract

Since the beginning of the COVID-19 pandemic in 2019-2020, Cytokine & Growth Factor Reviews has published several Special Issues focused on the biology, pathogenesis and therapeutic options in the treatment of COVID-19 infection, including articles on the involvement of the chemokine system in the cytokine storm in COVID-19, intervention in the early stages of COVID-19 pneumonia, the therapeutic value of corticosteroid treatment, early clinical intervention with type 1 interferons, progress in vaccine development, and organ specific complications of COVID-19. By 2022, multiple highly efficacious vaccines are available and are being administered in countries around the world, therapeutic options have been clinically evaluated and approved, and SARS-CoV-2 has arguably become the most thoroughly studied virus in history. But, with progress has also come unanticipated problems - misinformation, anti-vaxxers, opposition to protective masks, and politically motivated interference disguised as knowledge. With this issue of CGFR, we continue to document the global coronavirus pandemic and provide an update on the emergence of viral variants, the global effort to administer vaccines and the impediments to progress posed by misinformation and anti-vaccine sentiment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Daily update on cases, deaths and global hotspots by the Johns Hopkins University Coronavirus Resource Center.
Fig. 2
Fig. 2
Phylogenetic relationships among the main viral variants adapted from Nextstrain , (see nextstrain.org).
Fig. 3
Fig. 3
Technological platforms used to develop vaccines against COVID-19 , .
Fig. 4
Fig. 4
Rates of COVID-19 associated hospitalizations by vaccination status in adults ages 50–64 years, November-December 2021 .
Fig. 5
Fig. 5
Share of the population fully vaccinated against COVID-19, January 30, 2022 .
See this image and copyright information in PMC

References

    1. Coperchini F., Chiovato L., Croce L., Magri F., Rotondi M. The cytokine storm in COVID-19: an overview of the involvement of the chemokine/chemokine-receptor system. Cytokine and Growth Factor Rev. 2020;53:25–32. doi: 10.1016/j.cytogfr.2020.05.003. - DOI - PMC - PubMed
    1. Costela-Ruiz V.J., Illescas-Montes R., Puerta-Puerta J.M., Ruiz C., Melguizo-Rodríguez L. SARS-CoV-2 infection: the role of cytokines in COVID-19 disease. Cytokine and Growth Factor Rev. 2020;54:62–75. doi: 10.1016/j.cytogfr.2020.06.001. - DOI - PMC - PubMed
    1. Nile S.H., Nile A., Qiu J., Li L., Jia X., Kai G. COVID-19: pathogenesis, cytokine storm and therapeutic potential of interferons. Cytokine and Growth Factor Rev. 2020;53:66–70. doi: 10.1016/j.cytogfr.2020.05.002. - DOI - PMC - PubMed
    1. Sun X., et al. Cytokine storm intervention in the early stages of COVID-19 pneumonia. Cytokine and Growth Factor Rev. 2020;53:38–42. doi: 10.1016/j.cytogfr.2020.04.002. - DOI - PMC - PubMed
    1. Solinas C., Perra L., Aiello M., Migliori E., Petrosillo N. A critical evaluation of glucocorticoids in the management of severe COVID-19. Cytokine & Growth Factor Rev. 2020;54:8–23. doi: 10.1016/j.cytogfr.2020.06.012. - DOI - PMC - PubMed

Publication types